Dr. Reddy’s (RDY) and Alvotech (ALVO) announced that the FDA has accepted a 351(k) biologic license application submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia and Xgeva.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s, Alvotech announce FDA acceptance of BLA for AVT03
- Dr. Reddy’s Recalls Mislabelled Levetiracetam Injection in U.S.
- Dr. Reddy’s announces recall of Levetiracetam 0.75% Sodium Chloride injection
- Dr. Reddy’s Laboratories to Engage with Investors at Upcoming Conference
- Dr. Reddy’s Faces Tax Penalty, Evaluates Appeal